## 7 Results
### OT Study Analysis
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Study** & **Type of Drug** & **Indication for Drug Therapy** & **Time of Drug Exposure** \\ \hline \hline  & & \(23\times\) MM & \\ [PERSON] et al. & & \(5\times\) BC & NR \\
2006 [47] & NR & \(1\times\) UC & \\  & & \(1\times\) PC & \\ \hline [PERSON] et al. & & \(6\times\) BC & \\
2007 [48] & 9 \(\times\) ZOL & \(2\times\) MM & NR \\
2011 [49] & \(1\times\) PAM & \(1\times\) PC & NR \\  & & \(1\times\) nHL & \\ \hline  & & \(56\times\) MM & \\  & & \(41\times\) BC & \\ [PERSON] et al. & & \(11\times\) LC & \\
2012 [50] & NR & \(8\times\) PC & \\  & & \(8\times\) RC & \\  & & \(7\times\) OP, Lymphoma and TC & \\ \hline  & & \(11\times\) BC & \\ [PERSON] et al. & & \(4\times\) PC & \\
2012 [51] & \(24\times\) ZOL & \(4\times\) LC & Ranging from 10 to 18 months \\  & & \(3\times\) OP & \\  & & \(2\times\) MM & \\ \hline [PERSON] et al. & & \(1\times\) ZOL & \(1\times\) PC & 21 months ZOL; 48 months ALD \\
2014 [53] & \(1\times\) ALD + RES & \(1\times\) OP & + 24 months RES. \\ \hline \hline \end{tabular}
\end{table} 
Table 13: Preoperative pharmacological analysis: type of drugs, indication for drug therapy and time of drug exposure. Zoledronate acid (ZOL); Pamidornate (PAM); Alendronate (ALD); Risedronate (RES); Osteoporosis (OP); Multiple Myeloma (MM); Breast Cancer (BC); Prostate Cancer (PC); \({}^{\star}\) Unclear—the number expressed do not match the actual sample analysed; Not reported (NR); Non-Hodgkin Lymphoma (nHL); Lung Cancer (LC); Uterine Cancer (UC); Renal cancer (RC); Thyroid cancer (TC). \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Study** & **Type of Intervention** & \begin{tabular}{c} **Number of Cycles** \\ **Pre-Operative** \\ \end{tabular} & \begin{tabular}{c} **Number of Cycles** \\ **Post-Operative** \\ \end{tabular} & \begin{tabular}{c} **AAOMS Staging of** \\ **Disease** \\ \end{tabular} \\ \hline [PERSON] et al. & Surgical debridement + & \
\begin{tabular}{c} Unclear \\ ABX \\ \end{tabular} & Unclear &
\begin{tabular}{c} Unclear \\ \end{tabular} & Stage 1 \\ \hline [PERSON] et al. & & \(1\) (8 session of 3 min); \\
2007 [48] & Surgical debridement & \begin{tabular}{c} 1 (8 session of 3 min); \\ OT + ABX + antifungal \\ + Vitamin C \\ \end{tabular} & NR \\ \hline [PERSON] et al. & ABX + ultrasonic & \begin{tabular}{c} 3 to10 applications of \\ OT oil (mean \\ applications were 5.5) \\ \end{tabular} & None & \begin{tabular}{c} NR \\ ([PERSON] et al. 2007 \\ staging utilised) \\ \end{tabular} \\ \hline [PERSON] et al. & & \begin{tabular}{c} Curettage or \\ sequestrectomy \\ \end{tabular} & None & Unclear & NR \\ \hline [PERSON] et al. & \begin{tabular}{c} ABX followed by \\ SENB and/or \\ sequestrectomy \\ \end{tabular} & \begin{tabular}{c} 3 to 38 applications of \\ OT gas (mean \\ applications were \(11\)) \\ \end{tabular} & None & \begin{tabular}{c} No AAOMS used \\ ([PERSON] et al. 2007) \\ \end{tabular} \\ \hline [PERSON] et al. & \begin{tabular}{c} Debridement + ABX \\ (initially); eventually \\ radical surgery \\ \end{tabular} & \(7\) applications & None & Stage 2 \\ \hline [PERSON] et al. & \
\begin{tabular}{c} Mouthwash + Surgical \\ debridement \\ \end{tabular} & Unclear & None &
\begin{tabular}{c} Stage \(2\times 1\) \\ Stage NR \(\times 1\) \\ \end{tabular} \\ \hline \hline \end{tabular}
\end{table} 
Table 14: Ozone therapy (OT) operative analysis including type of intervention and the stage of the disease. Spontaneous expulsion of necrotic bone (SENB); antibiotics (ABX); American Association of Oral and Maxillofacial Surgery (AAOMS); not reported (NR). \begin{table}
\begin{tabular}{c c c c c c} \hline \hline \multirow{2}{*}{**Study**} & \multirow{2}{*}{**Follow-up Time**} & \multicolumn{2}{c}{**Type of Special Investigation**} & \multirow{2}{*}{**Treatment Complications**} & \multirow{2}{*}{**MRONJ Status after Treatment at the End of Follow-Up**} \\  & & & **Used during Patient’s** & & \\  & & & **Follow-Up** & & \\ \hline \hline [PERSON] et al. 2006 [47] & NR & NR & NR & NR \\ \hline \multirow{3}{*}{[PERSON] et al.